Qiming Star | Over 30 Qiming Venture Partners Portfolio Companies Named to 2025 China Biopharma Top 100 List
The compilation and release of the frontrunner rankings is a key initiative for identifying forward-looking trends, exploring the frontiers of technology, and establishing a "weather vane" for industry development.
Recently, the 2025 China Biopharma Top 100 list was unveiled at the 2025 Shanghai Biopharma Investment & Financing Summit and Fudan Biopharma Innovation Development Forum. Now in its third edition, the list recognizes benchmark companies across three sectors: biopharmaceuticals, medical devices, and digital health.
Thirty-five Qiming Venture Partners portfolio companies were selected: Ark Biosciences, LaNova Medicines, Minghui Pharma, Laekna Biopharma, Ticore Biotech, MediLink Therapeutics, Epigenic Therapeutics, OriCell Therapeutics, Zenitar, Changsen Pharma, Shize Biotech, Sunlight Bio, Zean Bioscience, Gloribio, NorthMind Life Sciences, DK MedTech, VINNO Medical, SceneRay, NuMax Medical, WuShuang Medical, Galenea Medical, Jieti Medical, Pulnovo Medical, DunBo Medical, Huimei Technology, DeepWise, Shukun Technology, InferVision, WeDoctor, Insilico Medicine, Yuanxin Technology, TandemAI, TandemAI, Beijing Zuoyi Technology Co., Ltd., and Zheng'an Health.
Ark Biosciences, LaNova Medicines, Minghui Pharma
(Excellence Leaders list)
Laekna Biopharma, Ticore Biotech, MediLink Therapeutics
Epigenic Therapeutics, OriCell Therapeutics, Zenitar, Changsen Pharma
(Innovation Pioneers list)
Shize Biotech, Sunlight Bio, Zean Bioscience
(Future Explorers list)
Gloribio
Selected for
(Rising Stars list)
China Biopharma Leaders · Biopharmaceuticals List
NorthMind Life Sciences, DK MedTech, VINNO Medical
(Excellence Leaders list)
SceneRay, NuMax Medical, WuShuang Medical
(Innovation Pioneers list)
Galenea Medical, Jieti Medical, Pulnovo Medical
(Future Explorers list)
DunBo Medical
(Rising Stars list)
Selected for
China Biopharma Leaders · Medical Devices List
Huimei Technology, DeepWise, Shukun Technology
InferVision, WeDoctor, Insilico Medicine, Yuanxin Technology
(Excellence Leaders list)
TandemAI
(Innovation Pioneers list)
TandemAI, Beijing Zuoyi Technology Co., Ltd.
(Future Explorers list)
Zheng'an Health
(Rising Stars list)
Selected for
China Biopharma Leaders · Digital Health List
Selection Criteria
· 2025 China Biopharma Top 100
Compared to the previous two editions, this year's list continues to align with the spirit of innovation and excellence that defines its honorees. In terms of organization, the list has expanded its partnership network: the organizers collaborated with Qiming Venture Partners and others to build ecosystem synergies, partnered with multiple media outlets to form a media matrix, and appointed compliance advisors for the list.
The selection process combines nomination and recommendation systems. For data collection, it integrates publicly available information with field research. For evaluation, it combines model-based scoring with expert review, drawing on broad input and collective wisdom to strengthen the list's credibility and expand its influence.
China's biopharma companies are moving from "innovation for innovation's sake" to "curated quality." In biopharmaceuticals, there is broad activity in next-generation modalities including cell and gene therapy, multispecific/bispecific antibodies, ADCs, PROTACs, nucleic acid drugs, and novel delivery technologies. In medical devices, breakthrough innovations abound in high-end imaging equipment, surgical navigation and robotics, high-throughput sequencing, and brain-computer interfaces. In digital health, AI-driven drug discovery, organoids, telemedicine, and digital therapeutics are expanding application scenarios while driving the delivery of quality medical resources to broader patient populations.
Moreover, China's biopharma companies are shifting from "going it alone" to "collaborative success." On the biopharmaceuticals front, biotech firms are actively exploring new financing models and pathways including License-out, Newco formations, royalty-based financing (RBF), and real-world asset tokenization (RWA), evolving from simple "product (technology) going global" to higher-level "asset operations." Big Pharma is pursuing M&A to shore up technical weaknesses and accelerate industrial chain integration. In medical devices, basic equipment has captured global market share through cost advantages and scaled production, while high-end products are gradually winning international recognition through cost-performance ratio and quality, achieving the leap from "Made in China" to "Chinese Brands." In digital health, AI drug discovery companies are producing an expanding stream of collaboration results with multinational pharmas in novel target and mechanism discovery, while internet healthcare and telemedicine have yielded substantial results in China's foreign medical assistance and regional public health prevention and control.
Source | Shanghai Biomedical Industry Promotion Center
Past Coverage
Qiming Stars | WeRide, Cornerstone Robotics Selected for 2025 Wealth China Best Design List
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.